SELUTION Sirolimus-Eluting Balloon For De Novo Coronary Lesions – New Evidence and Clinical Perspectives

The Latin American Society of Interventional Cardiology invites you to join a new virtual scientific event focused on the latest evidence and clinical perspectives from the SELUTION DeNovo study.

We will be joined by renowned specialists from Latin America and Europe, including Dr. Simon Eccleshall, Principal Investigator of the study.

The event is open, free of charge, and requires prior registration.

 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

 

More articles by this author

Fellow’s Corner – Case 2: Acute Myocardial Infarction Due to Simultaneous Occlusion of Two Coronary Arteries

Share your experience. Learn from experts. Grow as an interventional cardiologist. A new edition of the Fellow’s Corner is here, an academic exchange space designed...

Institutional Statement: SOLACI Expresses Its Solidarity with the People of Venezuela

The Latin American Society of Interventional Cardiology (SOLACI) expresses its deepest sorrow over the consequences of the earthquake that has affected Venezuela. We stand in...

V International Course on Cardiovascular Interventionism – SOLACI Scientific Endorsement

The Latin American Society of Interventional Cardiology (SOLACI) proudly grants its scientific endorsement to the V International Course on Cardiovascular Interventionism, an important academic...

Guatemala Sessions 2026 – Young Interventional Cardiologists Contest – Submit Your Case

The call for applications to participate in the Young Interventional Cardiologists Competition at the Guatemala 2026 Regional Sessions is now open. The event will...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Clinical and haemodynamic outcomes with contemporary intra- vs. supra-annular valves: The HERA-TAVI Registry

According to the latest European guidelines, transcatheter aortic valve implantation (TAVI) is the recommended treatment for patients aged ≥70 years with symptomatic severe aortic...

Redo-TAVI with SAPIEN 3: 30-Day Outcomes

The indications for transcatheter aortic valve implantation (TAVI) have rapidly expanded to include intermediate- and low-risk patients, extending its use to younger individuals with...

DAPT ≤30 Days After Drug-Coated Balloon Coronary Angioplasty

Drug-coated balloon (DCB) coronary angioplasty without stent implantation has become a well-established alternative in several clinical scenarios, particularly in patients at high bleeding risk...